Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study

By sjmartinez • December 26, 2025

Pistilli B, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Jañez NM, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Tsurutani J, Kalinsky K, Liedke PER, Carroll D, Khan S, Rugo HS, Xu B, Bardia A; TROPION-Breast01 investigators. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study. Ann Oncol. 2025 Dec 23:S0923-7534(25)06337-9. doi: 10.1016/j.annonc.2025.12.017. Epub ahead of print. PMID: 41448362.

Tags: Dato-DXd, Datopotamab deruxtecan, Hematology/Oncology, HER2-negative breast cancer, HR+ breast cancer, overall survival, Publications, TROPION-Breast01

Related Posts

Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene

Srinagesh HK, Gupta VK, Zhang A, Grunwald MR, Connor MP, Kota VK, Boccucci J, Ulrickson ML, Pradeep R, Hill LC, Tsai SB, O'Connor TE, Sandhu[...]

Neoadjuvant Stereotactic Body vs. Conventionally Fractionated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis

Shimizu T, Zheng S, Maeda S, Link J, Deranteriassian A, Premji A, King J, Girgis M, Hines OJ, Wainberg Z, Raldow A, He J, Burns[...]

Author Correction: Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis

Li S, Noor ZS, Zeng W, Stackpole ML, Ni X, Zhou Y, Yuan Z, Wong WH, Agopian VG, Dubinett SM, Alber F, Li W, Garon[...]